Protocol to Obtain Blood Samples for Leukemia Research

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00889031
Recruitment Status : Active, not recruiting
First Posted : April 28, 2009
Last Update Posted : March 19, 2018
Information provided by (Responsible Party):
Christopher H. Lowrey, Dartmouth-Hitchcock Medical Center

Brief Summary:
The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Condition or disease Intervention/treatment
Chronic Lymphocytic Leukemia Other: No Intervention

Detailed Description:
The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol to Obtain Blood Samples for Leukemia Research
Study Start Date : April 2009
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Group/Cohort Intervention/treatment
No Treatment Other: No Intervention
Patients with Chronic Lymphocytic Leukemia (CLL)

Primary Outcome Measures :
  1. To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis. [ Time Frame: 2 Years ]

Secondary Outcome Measures :
  1. To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine. [ Time Frame: 2 Years ]

Biospecimen Retention:   Samples With DNA
10cc of peripheral blood.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00889031

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center

Responsible Party: Christopher H. Lowrey, Professor of Medicine and of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center Identifier: NCT00889031     History of Changes
Other Study ID Numbers: D0905
First Posted: April 28, 2009    Key Record Dates
Last Update Posted: March 19, 2018
Last Verified: March 2018

Keywords provided by Christopher H. Lowrey, Dartmouth-Hitchcock Medical Center:

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell